Business

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive Officer and co-founder of BioNTech, […]

Orbit Discovery and start-up SanegeneBio have entered into a Master Service Agreement to identify tissue-specific delivery of a wide range of RNA therapeutics.  The agreement covers activities ranging from hit ID to cell-based internalisation studies, with an option for Sanegene to further develop the hits resulting from the screening activities.  Orbit’s technology enables the screening […]

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.  Cancer Focus Fund was established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising […]

Cancer Research Horizons and biotech company Turbine have announced a partnership to solve complex diseases.   The partnership will utilise Turbine’s Simulated Cells platform to identify target patient populations who could benefit from CDC7 inhibitor therapy with Cancer Research Horizons’ lead compound CRT’2199.   CRT’2199 originates from Cancer Research Horizons’ Therapeutic Innovation. CDC7 is a protein which […]

AmerisourceBergen Corporation has completed its acquisition of PharmaLex Holding, a provider of tech-enabled services from clinical development consulting to marketing authorisation.  PharmaLex is a global team of scientific, regulatory and safety and compliance (GxP) experts that provide strategic guidance and regulatory support to biopharma companies throughout a product’s lifecycle.  The acquisition of PharmaLex’s regulatory affairs, […]

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology.   Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments, plus royalties on net sales.  […]

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three cancer targets.  The collaboration will […]

China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major pharmaceutical markets (16MM).   As a result, the number of clinical trials conducted in the country for this indication is gradually increasing, driven mostly by international pharmaceutical companies.  According to GlobalData’s […]

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets.  Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform to conjugate proprietary antibodies from Merck KGaA, Darmstadt, […]

WuXi STA, a subsidiary of WuXi AppTec, has received scores of 60+ with a Silver rating from EcoVadis, a provider of business sustainability ratings, for its three sites in China.  The scores were received for active pharmaceutical ingredients (API) R&D and manufacturing from the Changzhou site, and for formulation development and manufacturing from the Shanghai […]